GIPL vs NEOG vs ZTS Stock Comparison

Global Innovative Platforms, Neogen and Zoetis Prices as of Oct 27, 2026 Peers: Industry group
NEOG Neogen Corp
$12.12 -11.7% 1M +96.8% 1Y
Market cap
$2.66B
P/E
–
Revenue (TTM)
$883.99M
Div. yield
–
Diagnostic Equipment Healthcare
1 win
ZTS Zoetis Inc.
$77.79 +8.9% 1M -46.5% 1Y
Market cap
$32.68B
P/E
12.5x
Revenue (TTM)
$9.52B
Div. yield
0.03%
Animal Health Healthcare
8 wins

Head to Head

10 decided of 12

Zoetis leads on 8 of the 12 questions below (Zoetis 8, Global Innovative Platforms 1, Neogen 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionGIPLNEOGZTSLeader
Larger companyMarket capitalisation $24.88M $2.66B $32.68B ZTS
Cheaper on earningsLower P/E, profitable companies only -36.0x -47.4x 12.5x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 37.9x 13.3x ZTS
Faster revenue growthRevenue growth, trailing twelve months — -0.3% +1.5% ZTS
More profitableNet margin, trailing twelve months -361.7% -6.3% 27.5% ZTS
Better return on capitalReturn on invested capital — -0.2% 23.4% ZTS
Less leveragedLower net debt / EBITDA 0.4x 5.4x 1.8x GIPL
Higher dividend yieldTrailing dividend yield — 0.00% 0.03% –
Better 1-year returnPrice return, last 12 months -37.5% +96.8% -46.5% NEOG
Better 5-year returnAnnualised price return, 5 years -36.9%/yr -22.1%/yr -18.5%/yr ZTS
Less volatileAnnualised volatility, 1 year 270.9% 55.7% 40.6% ZTS
Higher overall scoreMean of the five percentile scores vs peers 55/100 57/100 72/100 ZTS

Percentile Scorecard

GIPLNEOGZTS

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisGIPLNEOGZTS
Valuation 61 #244 of 625 73 #63 of 227 88 #76 of 625
Growth 27 #439 of 602 50 #111 of 219 52 #290 of 602
Profitability 39 #334 of 549 63 #76 of 205 96 #23 of 549
Financial Health 98 #12 of 654 46 #128 of 237 34 #435 of 654
Shareholder Returns 50 #184 of 367 55 #61 of 135 90 #39 of 367
Overall 55 57 72
  • GIPL ranked among 672 companies in Pharmaceuticals and Biotechnology
  • NEOG ranked among 247 companies in Medical Devices and Diagnostics
  • ZTS ranked among 672 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodGIPLNEOGZTSSPY
1 month 0.0%-11.7%+8.9% +0.9%
3 months 0.0%+28.9%-0.2% +5.9%
6 months -3.8%+34.5%-31.7% +8.5%
Year to date +354.5%+73.4%-38.2% +13.3%
1 year -37.5%+96.8%-46.5% +12.4%
3 years -52.4%-20.9%-50.1% +88.1%
3 years, per year -21.9%-7.5%-20.7% +23.5%
5 years -90.0%-71.4%-64.0% +68.2%
5 years, per year -36.9%-22.1%-18.5% +11.0%
10 years -79.2%-38.0%+60.2% +263.4%
10 years, per year -14.5%-4.7%+4.8% +13.8%

Risk

MeasureGIPLNEOGZTSSPY
Volatility, 1Y 270.9%55.7%40.6% 12.7%
Downside volatility, 1Y —46.7%49.2% 12.7%
Beta vs S&P 500, 1Y 2.261.440.52 1.00
Return / volatility, 1Y -0.141.74-1.14 0.98
Max drawdown, 5Y -98.0%-90.6%-72.0% -25.4%
From 52-week high -49.5%-13.3%-46.5% -0.9%
52-week high $0.99$13.98$145.41 $779.14
52-week low $0.11$5.41$69.12 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleGIPLNEOGZTS
P/E now vs peer median -36.0xmedian 17.4x -47.1xmedian 28.8x 12.4xmedian 17.4x
P/S now vs peer median 132.9xmedian 9.1x 3.0xmedian 3.0x 3.4xmedian 9.1x
EV/EBITDA now vs peer median -39.5xmedian 17.1x 29.3xmedian 17.4x 9.7xmedian 17.1x
P/FCF now vs peer median -32.5xmedian 19.0x 53.1xmedian 25.7x 13.9xmedian 19.0x
P/B now vs peer median 46.8xmedian 2.2x 1.3xmedian 2.4x 10.2xmedian 2.2x
PEG now vs peer median -0.57median 0.34 1.68median 1.03 1.32median 0.34

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsGIPLNEOGZTS
Revenue $187.20K $883.99M $9.52B
Gross profit – $418.98M $6.81B
Operating income -$677.04K -$7.38M $3.59B
Net income -$677.04K -$56.10M $2.62B
Free cash flow -$766.04K $49.80M $2.32B
R&D $377.99K $19.76M $722.00M
EPS (diluted) $-0.02 $-0.26 $6.26
Cash & equivalents $244.24K $172.00M $1.48B
Total debt $8.62K $774.20M $9.05B
Shares (diluted) 44.54M 218.10M 417.70M
Enterprise value $24.27M $1.99B $24.53B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricGIPLNEOGZTS
P/E -36.0x -47.1x 12.4x
P/FCF -32.5x 53.1x 13.9x
P/Operating cash flow -35.0x 31.0x 11.3x
P/S 132.9x 3.0x 3.4x
P/B 46.8x 1.3x 10.2x
P/Tangible book 47.1x 3.3x 14.4x
EV/EBITDA -39.5x 29.3x 9.7x
EV/EBIT -36.4x -440.3x 11.0x
EV/Revenue 131.6x 3.7x 4.2x
EV/FCF -32.2x 65.2x 17.1x
EV/Operating cash flow -34.7x 38.1x 13.9x
PEG (3Y EPS CAGR) -0.57 1.68 1.32

Growth

14 metrics
MetricGIPLNEOGZTS
Revenue growth (1Y) – -0.3% 1.5%
Revenue CAGR (3Y) – -1.3% 5.0%
Gross profit growth (1Y) – 1.8% 1.8%
Gross profit CAGR (3Y) – -3.1% 5.7%
Operating income growth (1Y) -20.9% 99.3% -0.1%
Operating income CAGR (3Y) -51.6% -29.0% 5.2%
Net income growth (1Y) -20.9% 94.6% 0.6%
Net income CAGR (3Y) -51.6% -28.3% 5.7%
EPS growth (1Y) -9.8% 94.6% 7.7%
EPS CAGR (3Y) 63.5% -28.0% 9.4%
Operating cash flow growth (1Y) 15.8% -1.9% -4.6%
Operating cash flow CAGR (3Y) -96.8% 2.9% 12.4%
Free cash flow growth (1Y) 9.2% 1,631% 2.1%
Free cash flow CAGR (3Y) -101.8% 126.1% 21.7%

Profitability

14 metrics
MetricGIPLNEOGZTS
Gross margin – 47.4% 71.5%
EBITDA margin -333.4% 12.5% 42.8%
Operating margin -361.7% -0.8% 37.7%
Pretax margin -361.7% -7.7% 34.4%
Net margin -361.7% -6.3% 27.5%
FCF margin -409.2% 5.6% 24.3%
Operating cash flow margin -379.8% 9.6% 29.8%
Return on equity -120.8% -2.7% 82.0%
Return on assets -119.7% -1.7% 17.3%
Return on invested capital – -0.2% 23.4%
Return on capital employed -121.4% -0.2% 27.5%
Asset turnover 0.3x 0.3x 0.6x
Cash conversion (OCF / net income) 1.1x -1.5x 1.1x
Stock comp / revenue – 1.3% 1.0%

Financial Health

11 metrics
MetricGIPLNEOGZTS
Debt / assets 1.0% 23.4% 60.0%
Debt / equity 0.0x 0.4x 2.9x
Net debt / EBITDA 0.4x 5.4x 1.8x
Debt / FCF 0.0x 15.5x 3.9x
Liabilities / assets 1.4% 36.8% 79.1%
Equity / assets 98.6% 63.2% 20.9%
Interest coverage – – 15.1x
Current ratio 34.7x 3.9x 3.1x
Quick ratio 33.2x 2.1x 1.6x
Cash ratio 31.3x 1.2x 0.8x
Altman Z-score 1,908 1.49 4.74

Shareholder Returns

7 metrics
MetricGIPLNEOGZTS
Dividend yield – – 2.7%
Net buyback yield -3.2% -0.1% 11.3%
Shareholder yield -3.2% -0.1% 14.0%
Payout ratio (earnings) – – 34.0%
Payout ratio (FCF) – – 38.4%
Dividend growth (1Y) – – 6.1%
Dividend CAGR (3Y) – – 10.9%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusGIPLNEOGZTS
Forward P/E – 37.9xFY2026 13.3xFY2026
EPS, next fiscal year – $0.32FY2026 $5.86FY2026
EPS growth, next FY – 0.0%FY2026 -8.6%FY2026
EPS growth, the year after – +31.3% +13.0%
Revenue, next fiscal year – $847.28MFY2026 $9.57BFY2026
Revenue growth, next FY – -2.7%FY2026 +1.0%FY2026
Revenue growth, the year after – -1.5% -7.9%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersGIPLNEOGZTS
Held by institutions – 100.0% 94.7%
Institutions holding – 315 1,417
Change in shares held, QoQ – +1.6% -2.6%
Institutions buying – 151 674
Institutions selling – 106 582
Buyers to sellers – 1.42 1.16

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

GIPLNEOGZTS
GIPL 1.00 0.01 0.02
NEOG 0.01 1.00 0.24
ZTS 0.02 0.24 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, GIPL, NEOG and ZTS?

Zoetis (ZTS) is the largest by market capitalisation: Global Innovative Platforms (GIPL) $24.88M, Neogen (NEOG) $2.66B, Zoetis (ZTS) $32.68B.

Which company is growing faster?

Zoetis (ZTS) grew revenue fastest over the trailing twelve months: Neogen (NEOG) -0.3%, Zoetis (ZTS) +1.5%.

Which company is more profitable?

Zoetis (ZTS) has the highest net margin (Global Innovative Platforms (GIPL) -361.7%, Neogen (NEOG) -6.3%, Zoetis (ZTS) 27.5%). On return on invested capital, Zoetis (ZTS) leads (Neogen (NEOG) -0.2%, Zoetis (ZTS) 23.4%).

Which stock has performed better?

Over the past year Neogen (NEOG) returned the most: Global Innovative Platforms (GIPL) -37.5%, Neogen (NEOG) +96.8%, Zoetis (ZTS) -46.5%. Over five years, Zoetis (ZTS) compounded fastest (Global Innovative Platforms (GIPL) -36.9%/yr, Neogen (NEOG) -22.1%/yr, Zoetis (ZTS) -18.5%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Neogen (NEOG) 0.00%, Zoetis (ZTS) 0.03%. Global Innovative Platforms (GIPL) and Neogen (NEOG) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Zoetis (ZTS) has been the steadiest (Global Innovative Platforms (GIPL) 270.9%, Neogen (NEOG) 55.7%, Zoetis (ZTS) 40.6%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, GIPL, NEOG and ZTS?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Zoetis (ZTS) leads on 8. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.